| Tumor-infiltrating lymphocytes in the immunotherapy era ST Paijens, A Vledder, M de Bruyn, HW Nijman Cellular & molecular immunology 18 (4), 842-859, 2021 | 698 | 2021 |
| Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy A León-Castillo, SM De Boer, ME Powell, LR Mileshkin, HJ Mackay, ... Journal of Clinical Oncology 38 (29), 3388-3397, 2020 | 641 | 2020 |
| POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo, E Marchi, M de Bruyn, ... Clinical Cancer Research 21 (14), 3347-3355, 2015 | 329 | 2015 |
| Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ... The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016 | 323 | 2016 |
| cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers C Hong, M Schubert, AE Tijhuis, M Requesens, M Roorda, ... Nature 607 (7918), 366-373, 2022 | 217 | 2022 |
| A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer HH Workel, JM Lubbers, R Arnold, TM Prins, P van der Vlies, K de Lange, ... Cancer immunology research 7 (5), 784-796, 2019 | 201 | 2019 |
| Therapeutic potential of Galectin‐9 in human disease VR Wiersma, M de Bruyn, W Helfrich, E Bremer Medicinal research reviews 33 (S1), E102-E126, 2013 | 184 | 2013 |
| CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer FL Komdeur, TM Prins, S van de Wall, A Plat, GBA Wisman, H Hollema, ... Oncoimmunology 6 (9), e1338230, 2017 | 179 | 2017 |
| MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells TS Stutvoet, A Kol, EGE de Vries, M de Bruyn, RSN Fehrmann, ... The Journal of pathology 249 (1), 52-64, 2019 | 164 | 2019 |
| CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma HH Workel, FL Komdeur, MCA Wouters, A Plat, HG Klip, FA Eggink, ... European journal of cancer 60, 1-11, 2016 | 158 | 2016 |
| Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for … FA Eggink, IC Van Gool, A Leary, PM Pollock, EJ Crosbie, L Mileshkin, ... Oncoimmunology 6 (2), e1264565, 2017 | 143 | 2017 |
| Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats Y Wei, P Chen, M de Bruyn, W Zhang, E Bremer, W Helfrich BMC gastroenterology 10, 1-9, 2010 | 140 | 2010 |
| Tumour-infiltrating lymphocytes: from prognosis to treatment selection K Brummel, AL Eerkens, M de Bruyn, HW Nijman British Journal of Cancer 128 (3), 451-458, 2023 | 132 | 2023 |
| Tertiary lymphoid structures critical for prognosis in endometrial cancer patients N Horeweg, HH Workel, D Loiero, DN Church, L Vermij, A Léon-Castillo, ... Nature Communications 13 (1), 1373, 2022 | 101 | 2022 |
| Treatment regimen, surgical outcome, and T-cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high-grade serous ovarian cancer MCA Wouters, FL Komdeur, HH Workel, HG Klip, A Plat, NM Kooi, ... Clinical Cancer Research 22 (3), 714-724, 2016 | 101 | 2016 |
| Antibody-based fusion proteins to target death receptors in cancer M de Bruyn, E Bremer, W Helfrich Cancer letters 332 (2), 175-183, 2013 | 99 | 2013 |
| Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo M de Bruyn, AA Rybczynska, Y Wei, M Schwenkert, GH Fey, ... Molecular cancer 9, 1-14, 2010 | 94 | 2010 |
| CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy FL Komdeur, MCA Wouters, HH Workel, AM Tijans, ALJ Terwindt, ... Oncotarget 7 (46), 75130, 2016 | 92 | 2016 |
| A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability B Ten Cate, E Bremer, M De Bruyn, T Bijma, D Samplonius, ... Leukemia 23 (8), 1389-1397, 2009 | 90 | 2009 |
| Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects P Eggleton, E Bremer, JM Tarr, M de Bruyn, W Helfrich, A Kendall, ... Arthritis research & therapy 13, 1-15, 2011 | 81 | 2011 |
